S
Sunil Pancholi
Researcher at Breast Cancer Now
Publications - 27
Citations - 1704
Sunil Pancholi is an academic researcher from Breast Cancer Now. The author has contributed to research in topics: Estrogen receptor & Breast cancer. The author has an hindex of 17, co-authored 25 publications receiving 1414 citations. Previous affiliations of Sunil Pancholi include Institute of Cancer Research & The Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Maria Teresa Herrera-Abreu,Marta Palafox,U. Asghar,Martín A. Rivas,Rosalind J. Cutts,Isaac Garcia-Murillas,Alex Pearson,Marta Guzman,Olga Rodriguez,Judit Grueso,Meritxell Bellet,Javier Cortes,Richard Elliott,Sunil Pancholi,José Baselga,Mitch Dowsett,Lesley-Ann Martin,Nicholas C. Turner,Nicholas C. Turner,Violeta Serra +19 more
TL;DR: It is reported that ER-positive breast cancer cells can adapt quickly to CDK4/6 inhibition and evade cytostasis, in part, via noncanonical cyclin D1-CDK2-mediated S-phase entry, highlighting strategies to prevent the acquisition of therapeutic resistance to these agents.
Journal Article
Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
Stephen R. D. Johnston,Julia Head,Sunil Pancholi,Simone Detre,Lesley-Ann Martin,Ian E. Smith,Mitch Dowsett +6 more
TL;DR: Clinical trials are in progress to determine the safety and optimal schedule for each of the various STIs, and studies of STIs in combination with aromatase inhibitors have commenced in breast cancer to see whether the therapeutic response to endocrine therapy can be enhanced further.
Journal ArticleDOI
Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.
Ivan Plaza-Menacho,Andrea Morandi,David J. Robertson,Sunil Pancholi,S. Drury,S. Drury,Mitch Dowsett,Mitch Dowsett,Lesley-Ann Martin,Clare M. Isacke +9 more
TL;DR: In ERα-positive breast cancer cells, activation of the receptor tyrosine kinase RET by its ligand GDNF results in increased ERα phosphorylation on Ser118 and Ser167 and estrogen-independent activation of ERα transcriptional activity.
Journal ArticleDOI
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
Lesley-Ann Martin,Ricardo Ribas,Nikiana Simigdala,Eugene Schuster,Sunil Pancholi,Tencho Tenev,Pascal Gellert,Laki Buluwela,Alison Harrod,Allan Thornhill,Joanna Nikitorowicz-Buniak,Amandeep Bhamra,Marc-Olivier Turgeon,George Poulogiannis,George Poulogiannis,Qiong Gao,Vera Martins,Margaret Hills,Isaac Garcia-Murillas,Charlotte Fribbens,Neill Patani,Zheqi Li,Matthew J. Sikora,Nicholas C. Turner,Wilbert Zwart,Steffi Oesterreich,Jason S. Carroll,Simak Ali,Mitch Dowsett,Mitch Dowsett +29 more
TL;DR: The first discovery of naturally occurring ESR1Y537C and ESR2Y537S mutations in two breast cancer cell lines after acquisition of resistance to long-term-estrogen-deprivation and subsequent resistance to fulvestrant is reported.
Journal ArticleDOI
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors
Andrea Morandi,Lesley-Ann Martin,Qiong Gao,Sunil Pancholi,Alan Mackay,David Robertson,Marketa Zvelebil,Mitch Dowsett,Ivan Plaza-Menacho,Clare M. Isacke +9 more
TL;DR: The results establish GDNF-RET signaling as a rational therapeutic target to combat or delay the onset of aromatase inhibitor resistance in breast cancer.